<DOC>
	<DOCNO>NCT00446225</DOCNO>
	<brief_summary>A Phase III , multicenter , open-label , randomized trial Erlotinib ( Tarceva® ) versus chemotherapy patient advance NSCLC mutation Tyrosine Kinase ( TK ) domain EGFR .</brief_summary>
	<brief_title>Phase III Study ( Tarceva® ) v Chemotherapy Treat Advanced Non-Small Cell Lung Cancer ( NSCLC ) Patients With Mutations TK Domain EGFR</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Inclusion criterion : Informed consent Histologically confirm diagnosis NSCLC , non epidermoid , stage IV IIIB pleural effusion , N3 tumours candidate thoracic radiotherapy , harbour deletion exon 19 mutation exon 21 TK EGFR . Either measurable evaluable disease . Age &gt; 18 year . ECOG performance status &lt; 2 . Adequate bone marrow function Adequate renal function Adequate hepatic function Patients must accessible treatment followup . Patients capable follow adequate therapeutic compliance Women child bear potential : negative pregnancy test . Patients gender fertile age , include woman last menstruation within two previous year , must follow effective contraceptive measure . Ability swallow . Patients asymptomatic brain metastasis stable medical treatment eligible study . Patients receive radiotherapy brain metastasis prior systemic treatment NSCLC also eligible . Absence gastrointestinal tract problem Exclusion criterion : Pregnant lactate woman . Women child bear potential positive pregnancy test basal visit accomplish test . Patients gender sexually active ( fertile age ) follow contraceptive measure study . Prior chemotherapy metastatic disease . Both prior neoadjuvant adjuvant chemotherapy allow provide complete â‰¥ 6 month enter study . Prior treatment EGFR target therapy . Patients may receive radiotherapy , provide irradiated lesion evaluable lesion response complete enter study . Prior experimental pharmacological agent within 3 week prior inclusion study . Any significant ophthalmologic impairment eye surface . Use contact lens recommend . Preexisting motor sensorial neurotoxicity grade &gt; 2 , accord NCICTC criterion . Evidence spinal cord compression . Inability take oral medication surgical procedure affect absorption imply intravenous parenteral feeding . Any severe disease clinical condition , , : Unstable cardiopathy despite treatment , myocardial infarction within 6 month enter study History significant neurological psychiatric disorder , include dementia epileptic seizure . Uncontrolled active infection . Uncontrolled peptic ulcer . Unstable diabetes mellitus contraindication treatment corticosteroid . AST and/or ALT &gt; 1.5 x UNL associate alkaline phosphatase &gt; 2.5 x UNL . Any underlie severe process affect ability take part study . Absolute contraindication steroid . Dementia significant mental disorder interfere understand give informed consent . History malignancy except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , radically treat prostatic carcinoma good prognostic ( Gleason = 6 ) . History curatively treat malignancy evidence disease within past 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Lung</keyword>
	<keyword>cancer</keyword>
	<keyword>EGFR</keyword>
	<keyword>Epidermal Growth Factor Receptor</keyword>
	<keyword>tyrosine kinase</keyword>
	<keyword>Tarceva®</keyword>
	<keyword>Erlotinib</keyword>
</DOC>